TrialBlood advances2020

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.

John O Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.